Business Wire

Akthelia Pharmaceuticals and the University of Iceland Secure a €6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)

Share

Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, and the University of Iceland, are proud to announce the successful joint award of a €6 million EU Horizon Grant to fund the groundbreaking IN-ARMOR project. The project seeks to address antimicrobial resistance (AMR), a major global health threat identified by the World Health Organization (WHO) as one of the top 10 health challenges of our time.

AMR and multi-drug resistance contribute to over 5 million deaths per year, with the potential to give rise to the next global pandemic as 'pan-drug' resistant strains emerge. As traditional antibiotics lose effectiveness, alternative therapeutic approaches are urgently needed.

"We are thrilled that our cutting-edge technology, developed in collaboration with the University of Iceland, has received this prestigious grant," said Egill Masson, CEO of Akthelia Pharma, "The IN-ARMOR project focuses on novel immune system inducers and is a testament to the potential of our approach to address the global challenge of antimicrobial resistance. The funding propels our ground-breaking research to address not only infections caused by bacteria but also inflammation and the challenge of viral and fungal infections, where fewer treatment options exist."

"I am delighted to collaborate with Akthelia Pharmaceuticals on this critical initiative," commented Professor Gudmundur Gudmundsson, Professor of Cell Biology at the University of Iceland and leading authority on innate immunology, "By focusing on enhancing innate immunology, we have the opportunity to move beyond traditional antibiotics towards next generation therapies that could revolutionize the way we combat antimicrobial resistance, ultimately protecting countless lives worldwide."

The IN-ARMOR project brings together nine universities, research institutes, and seven medical and industry partners across nine EU countries. The project's goal is to introduce a novel class of immune system inducers to enhance the body's innate microbial defense mechanisms, combating AMR and reducing the incidence of 13 of the most dangerous infections, including two of the top three priority-1 infections. Horizon Europe is the EU’s key funding program for research and innovation with a budget of €95.5 billion.

Employing computer-aided drug design and in-silico approaches, alongside a nanotech-based drug delivery system, IN-ARMOR will optimize an existing drug platform for its first target indication. The therapy will undergo pre-clinical validation for safety and efficacy, meeting all investigational medicinal product requirements.

Upon completion, IN-ARMOR will advance to clinical validation, with the potential to save over 4 million lives worldwide and significantly reduce the burden of antibiotic development, leading to long-term cost reduction impact of €107BN and reduction in global disease burden of 97 million DALYs.

Akthelia Pharmaceuticals is committed to addressing the global threat of antimicrobial resistance and believes that the IN-ARMOR project is a vital step towards a healthier future.

ABOUT AKTHELIA PHARMACEUTICALS

Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.

Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Egill Masson
CEO
egill.masson@aktheliapharma.com

Akthelia Pharmaceuticals
Grandagarði 16
101 Reykjavik
Iceland

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Paymentology Launches PayCredit to Power Credit Innovation for Digital Banks and Fintechs22.10.2025 11:00:00 EEST | Press release

Paymentology, the leading global issuer-processor, has launched PayCredit, an advanced credit ledger platform designed to help financial institutions deliver tailored, feature rich credit products at speed, overcoming the limitations of legacy and core banking systems. Amid rising demand for flexible financial payment tools, credit cards remain a critical instrument for enabling consumer spending, managing cash flow, and deepening customer loyalty. Yet many legacy credit systems lack the flexibility to meet the expectations of today's consumers, who demand a combination of both revolving and instalment credit to help them better manage their money, whilst many modern ledgers are retrofitted from a debit architecture and struggle to provide credit processing. PayCredit was developed from the ground up with credit billing cycles and logic at its core, making it easier for issuers to build products that reflect real-world behaviours, from revolving balances to instalments and Buy Now, Pay

Infrastructure Capital Advisors Expands its Offerings into European Markets With Launch of Preferred Income UCITS ETF (PFFI) & Declares The Fund’s First Dividend22.10.2025 11:00:00 EEST | Press release

Infrastructure Capital Advisors (“Infrastructure Capital”), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is celebrating the expansion of its offerings into Europe with the launch of the Infrastructure Capital Preferred Income UCITS ETF (PFFI). This actively managed ETF, which was listed in September, seeks to produce diversified income by targeting high yield income investments by predominately focusing on preferred stocks. Today,PFFI is also declaring its first dividend of $0.1335 per share ($1.602 per share on an annualized basis). The dividend will be paid on November 3, 2025 to shareholders of record as of the close of business on October 29, 2025. “We are thrilled to offer investors across a range of global markets the opportunity to benefit from our team’s active management process applied to preferred and income securities as we identify and capitalize on market inefficiencies,” said Jay Hatfield, CEO of Infrastruc

Locus Robotics Reports Record Growth Achieving 6 Billion Picks in Fastest Time Yet22.10.2025 11:00:00 EEST | Press release

Locus Robotics, the global leader in AI-driven, mobile warehouse automation, today announced its strongest growth over the past two quarters, reflecting accelerating industry adoption of Physical AI, seamlessly fusing intelligent robotics and real-world execution. Driven by surging implementations and faster time-to-value for customers, Locus Robotics recently surpassed 6 billion picks worldwide, with the last billion in just 24 weeks—the fastest pace in its history. “Our growth is driven by our customers’ success,” said Rick Faulk, CEO of Locus Robotics. “Retailers, 3PLs, and healthcare providers are seeing measurable impact faster than ever—scaling productivity in weeks, not months. Staples Canada, for example, hit one million picks just 70 days after going live, proving the immediate ROI our platform delivers.” So far this year, Locus Robotics has seen 30–40% year-over-year volume growth, with throughput reaching 200–300 units picked per second — roughly 45 million picks per week. L

Smartstream and ActiveViam Collaborate to Meet Demands for Collateral Optimisation22.10.2025 10:55:00 EEST | Press release

Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces the partnership with ActiveViam, a global provider of advanced data analytics and decision-making solutions for financial services – together the two companies will provide immediate ROI for collateral management optimisation, for clients in treasury and capital markets. This collaboration connects two technologies, Smartstream’s Smart Collateral with ActiveViam’s Atoti Collateral Optimisation solution. The result is an efficient, streamlined and cost-effective solution for optimising and allocating cheaper-to-deliver assets, whilst reducing reliance on expensive liquidity buffers. The partnership provides a comprehensive, and modular collateral management workflow for financial institutions. This powerful combination future-proofs clients and enables them to make more efficient use of their cash and non-cash collateral inventory in a timely manner. Roland Brandli

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 10:30:00 EEST | Press release

Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingham NHS Foundation Trust, today announced new overall survival (OS) insights from the PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) Study aligning with previous findings that suggest mogamulizumab may offer meaningful OS benefit for patients living with mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL).2 Key findings2: For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those not receiving mogamulizumab (n=175) at 54 months (p<0.01). Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye